In the current study, we aim to elucidate whether histone deacetylase 3 (HDAC3) exerts oncogenic role in GC, and investigate the possible mechanism.
Cancer Gene Ther. 2020 Jul 13.
"This study suggested that crizotinib was an offthe-shelf, practical, and ostensibly effective treatment option for patients with ovarian cancer with ROS1 rearrangement. NGS-based genetic testing may guide to plan therapeutic paradigms, and render precision medicine promising in ovarian cancer treatment."
Oncologist. 2020 Jul 11.
Pyrotinib showed promising antitumor activity and an acceptable safety profile in chemotherapytreated patients with HER2-mutant NSCLC.
J Clin Oncol. 2020 Jul 2;JCO2000297.
In our study, we established predictive models based on radiomic analysis of 18F-FDG PET/CT images. And it achieved a satisfying prediction power in the identification of EGFR mutation status as well as the certain EGFR mutation subtypes in lung cancer.
Transl Lung Cancer Res. 2020 Jun; 9(3): 549–562.
Variations in the incidence of mutations in signaling pathways involved in lung adenocarcinoma and the correlation of the signaling pathways with TMB may exist across different ethnic groups.
Transl Lung Cancer Res. 2020 Jun; 9(3): 629–638.
"Pemetrexed-based chemotherapy remains an important component of care for patients with HER2-mutant NSCLC. HER2-TKI given as an initial therapy may bring more clinical benefits than when given as a subsequent-line therapy. Refining the patient population based on patterns of HER2 variants may help improve the efficacy of anti-HER2 treatment in lung cancer. Developing highly effective and tolerable HER2-targeted agents is urgently needed for this population."
Ther Adv Med Oncol. 2020 Jun 27;12:1758835920936090.